gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
The anti-HER2 antibody binds HER2 and is internalized; lysosomal cleavage releases deruxtecan, a topoisomerase I inhibitor, causing DNA damage and death of HER2+ cells. The Fc domain can also trigger ADCC; the payload may exert a bystander effect on neighboring cells.
enzyme_product
On
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Antibody component (trastuzumab) binds extracellular domain of HER2 receptor tyrosine kinase
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06085755
disease_id_num_tar_ref
1155
drug_id_num_tar_ref
3153